GlassScriptPhysician profile
William N Bedingfield
NPI 1598764524
$7,298.59
in general payments reported to CMS, 2019-2025
61 companies · $1,854 in 2025
The $1,854 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $290 · 2021: $613 · 2022: $838 · 2023: $1,745 · 2024: $1,547 · 2025: $1,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,145.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,316.75 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $1,066.57 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $550.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Teva Pharmaceuticals USA, INC. | $507.83 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $486.54 | 2019-2024 | |
| Lundbeck LLC | $308.33 | 2024-2025 | Vyepti, Rexulti |
| Eisai INC. | $256.48 | 2021-2025 | |
| Glaxosmithkline, LLC. | $255.54 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $184.12 | 2021-2025 | Rexulti, Nuedexta |
| Acadia Pharmaceuticals INC | $183.83 | 2024-2025 | Nuplazid |
| Xeris Pharmaceuticals, INC. | $116.42 | 2023-2024 | Gvoke Hypopen |
| Amgen INC. | $109.65 | 2019-2023 | Aimovig |
| Dexcom, INC. | $103.37 | 2021-2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $99.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Argenx US, INC. | $96.11 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bedingfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.